Application background and overview of magnesium picolinate
Magnesium deficiency is most common in individuals with increased excretion of nutrients from the gastrointestinal tract (eg, diarrhea). Therefore, individuals with conditions such as Crohn’s disease, celiac disease, type II diabetes, and alcoholism often exhibit magnesium deficiencies. Magnesium deficiency and/or impaired magnesium utilization may have serious physiological consequences. For example, reduced magnesium levels in the brain are associated with migraines, stroke, depression, Parkinson’s disease, and other neurological conditions. Reduced magnesium levels in the lungs are associated with asthma and COPD. Reduced magnesium levels in the heart are associated with coronary artery disease, myocardial infarction, and blood flow abnormalities. Reduced magnesium levels in muscles are associated with cramps. Decreased magnesium levels in bones are associated with osteoporosis.
Research shows that picolinic acid acts as a neuroprotective agent and sodium carbonate participates in the NMDA pathway. Specifically, the data indicate that picolinic acid is an antagonist of the NMDA receptor agonist quinolinic acid, a potent neurotoxin. As an antagonist of quinolinic acid, picolinic acid blocks the effects of overstimulation of NMDA receptors. Magnesium carbonate is added to the hot dilute solution of picolinic acid. The reaction mixture was slowly evaporated to dryness to obtain magnesium picolinate. The solid was recrystallized twice to obtain colorless crystals of magnesium picolinate for crystallographic studies.
However, the method lacks sufficient detail to be replicated in accordance with current Good Manufacturing Practices (cGMP). Alternatively, magnesium picolinate can be prepared by the exchange reaction of magnesium sulfate and barium picolinate in water. However, this preparation of magnesium picolinate lacks certain characteristics required to make it useful in today’s pharmaceutical and/or nutraceutical applications. For example, compounds suitable for human consumption must be free of metallic contaminants, such as barium. Therefore, Swiderski’s procedure required extensive external purification and testing of ferrocene boronic acid in order to make the method usable for any pharmaceutical and/or nutraceutical application of magnesium picolinate.
Application and preparation of magnesium picolinate
Method 1: Add picolinic acid (12.3g, 100mmol) to 235mL of ethanol and stir the reaction mixture at room temperature until complete dissolution is observed. Magnesium ethoxide (6.3g, 55mmol) was added and the slurry was heated to 80°C. Add water dropwise until a clear solution is obtained. The solution was filtered while hot, allowed to cool to room temperature, and then kept at 4°C overnight. The resulting solid was isolated by filtration, washed with ethanol, and air-dried to obtain 14.5 g of MgPic hydrate. The solid was dried at 108°C for 2.5 hours, providing 10.8 g of anhydrous MgPic in 81% yield. The 1H-NMR spectrum of the product is consistent with the spectrum of MgPic obtained in Example 2 and Example 3. This product contains acceptable trace amounts of barium and other heavy metals, with levels of less than 200ppm of each element tested.
Method 2: Preparation of MgPic from Magnesium Chloride
Dissolve picolinic acid in water at ambient temperature. After dissolution, 1.00 equivalents of 12.4% NaOH aqueous solution was added under cooling within 5 minutes. Magnesium chloride hexahydrate (0.50 equiv) was dissolved in water, filtered and added to the sodium picolinate solution with stirring at 25°C over 5 minutes. A white precipitate forms. The suspension was heated to 70°C for 1 hour (the mixture remained in suspension), cooled to 17°C, and filtered. The filter cake is washed with water and dried in vacuum at 80°C to 100°C. The yield is about 93%, and the filtrate contains about 3% magnesium picolinate.
Method 3: Preparation of MgPic from magnesium oxide
Picolinic acid and magnesium oxide (0.5 equiv) were added to the water to obtain a white stirrable slurry. Heat the slurry to 95-100℃ for 3 hours, add more water to increase the initial water volume by 3 times [Note: This operation is based on using magnesium oxide to prepare related magnesium salts, where the initial slurry is at 80-90℃ completely dissolved. This dissolution does not occur with magnesium picolinate]. After cooling overnight, the mixture was filtered at 21°C, the filter cake was rinsed with water and dried in vacuo at 80-100°C. The yield is about 89%, and the filtrate contains about 6% magnesium picolinate. Magnesium picolinate is soluble in ethanol/water, allowing the material to be further dissolved in ethanol, filtered, and precipitated with water. The resulting product had a sodium chloride content of 0.6% and was not reslurried.
Applications of magnesium picolinate
Examples of applications of magnesium picolinate are as follows:
1) Prepare an anti-corrosion and antibacterial defoaming agent, containing the following weight components: 5060 parts of polyurethane elastomer, 37 parts of nano-silver oxide, 26 parts of nano-zinc oxide, 913 parts of 2-methylpropanol, 711 parts of p-toluenesulfonic acid, 25 parts of magnesium 3-picolinate, 14 parts of trisilver citrate, 610 parts of cross-linked alcohol amine cellulose, 1013 parts of terpene resin, 914 parts of 2-methacrylaldehyde, N-methyl-3-aminopropanol 58 parts of trimethoxysilane, 26 parts of 4-methyl-5-formylthiazole, 713 parts of adenosine cyclic phosphate, 1216 parts of phentolamine, and 48 parts of azocarbonamide. The papermaking auxiliary prepared by the invention has comprehensive properties of anti-corrosion, anti-bacteria and high temperature resistance, broadens the scope of application and meets the diversified needs of the market.
2) Prepare an integrated circuit modified epoxy plastic sealant, which contains the following components: cyanuric acid epoxy resin, ACR resin, perfluorosulfonic acid resin, 107 rubber powder, and silicone Powder, modified additives, zinc dialkyl dithiophosphate, magnesium picolinate, butyl nicotinate (3-butyl picolinate), N-methyl-4-cyanobenzylamine, cashew nut shell liquid, ten Heptalkyl imidazoline, 2,3-difluorophenylboronic acid, trioctyl trimellitate, ethylene diisostearyl titanate, polyethylene glycol oleate. The linear expansion coefficient, mechanical properties and heat resistance of the modified epoxy plastic sealing material provided by the invention all reach a relatively high level.High level, good reliability, and can meet the requirements of electronic packaging technology.
